Fig. 3: Association between plasma GS-CA1 and protection from SHIV challenge.
From: Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
a, Plasma levels of GS-CA1 measured by mass spectrometry among individual rhesus macaques (n = 8) treated with a 150 mg kg−1 dose over time. Black circles represent time points before the first detection of viraemia. Red circles represent time points including and after the first detection of viraemia. Grey shaded boxes represent serum Env ELISA seroconversion time points. The bottom dotted line represents the assay LOD (1 nM). The bottom and top dashed lines represent one and two times the rhesus paEC95, respectively. b, Same data as in a for rhesus macaques treated with GS-CA1 at a dose of 300 mg kg−1. No signal above the assay LOD was observed among the eight placebo-treated control animals throughout the study.
